Agonist News and Research

RSS

Altering the circadian rhythm: an interview with Dr. Doug Kojetin, The Scripps Research Institute

The circadian rhythm is affected by many different stimuli—such as sleep and light, which are the most broadly appreciated ways—but also eating— all of which can modulate, or change, important processes in our bodies such as temperature, production of hormones or other signalling small molecules, cellular regeneration, and others.

6 Aug 2014

New approach for understanding auditory localization in patients with hearing aids under background noise

Patients with implanted artificial cochlea often complain that they cannot recognize speech well in natural environments, especially if background of noise is present.

6 Aug 2014

Naltrexone may be effective in diminishing ICD symptoms in PD patients, study finds

Up to 20 percent of Parkinson's disease (PD) patients and their families may confront a common but largely unrecognized challenge: the occurrence of impulse control disorders (ICDs) such as compulsive gambling, sexual behavior, eating, or spending.

31 Jul 2014

GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

GSK today announced that once-weekly Tanzeum (albiglutide), a prescription injectable treatment for type 2 diabetes in adults, as an adjunct to diet and exercise, is now available in pharmacies throughout the U.S.

29 Jul 2014

Combination superior to monotherapy for COPD

Combination treatment with umeclidinium plus vilanterol improves lung function in patients with chronic obstructive pulmonary disease to a greater extent than with VI or tiotropium monotherapy, results show.

22 Jul 2014

Long-acting inhaled combination therapy best for COPD

The combination of a long-acting β22-agonist and an inhaled corticosteroid may be the best choice for some patients with chronic obstructive pulmonary disease who need more than short-acting bronchodilators, suggest the results of a Cochrane Collaboration network meta-analysis.

22 Jul 2014

New guidelines integrate biomedical advances and behavioral interventions for HIV people

In an innovative approach to HIV prevention, an interdisciplinary group of experts has come together for the first time to lay out a framework of best practices to optimize the role of the clinician in achieving an AIDS-free generation.

21 Jul 2014

Study demonstrates that Parkinson's patients are more creative than their healthy peers

Prof. Rivka Inzelberg of Tel Aviv University's Sackler Faculty of Medicine and the Sagol Neuroscience Center at Sheba Medical Center, Tel Hashomer, documented the exceptional creativity of Parkinson's patients two years ago in a review for Behavioral Neuroscience. Since then, she has conducted the first empirical study to verify a link between Parkinson's disease and artistic inclination.

15 Jul 2014

Sleep problems in PD patients can worsen in later stages of disease

Up to 70% of Parkinson's disease (PD) patients experience sleep problems that negatively impact their quality of life.

11 Jul 2014

New class of anti-arthritic drugs reduce arthritic joint inflammation and periodontitis

Inflammatory diseases can occur simultaneously in distinct sites in the same patient, complicating treatment because a medication effective for one disorder may exacerbate the other.

10 Jul 2014

Scientists discover new role for pair of compounds which alter circadian rhythm

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have discovered a surprising new role for a pair of compounds—which have the potential to alter circadian rhythm, the complex physiological process that responds to a 24-hour cycle of light and dark and is present in most living things.

8 Jul 2014

Scientists discover new compounds that could alter circadian rhythm

8 Jul 2014

New technology in field of optogenetics can remotely control specific receptors by light

Institute for Basic Science (IBS), the main organization of the International Science and Business Belt project in South Korea, has announced that a group of researchers, led by professor Won Do Heo, have developed a new technology in the field of optogenetics that can remotely control specific receptors by light.

8 Jul 2014

Grunenthal Group submits Marketing Authorization Application to EMA for ZALVISO

AcelRx Pharmaceuticals, Inc. and Grunenthal Group announced today that Grunenthal has submitted a Marketing Authorization Application (MAA) to the European Medicines Authority for ZALVISO for the management of moderate to severe acute pain in adult patients in a medically supervised environment.

7 Jul 2014

Galderma's trifarotene molecule gets FDA Orphan Drug Designation for treatment of congenital ichthyosis

Galderma announces that the U.S. FDA granted Orphan Drug Designation status for the company's trifarotene molecule for the treatment of congenital ichthyosis. Based on this decision, Galderma plans to implement a clinical development plan, reinforcing its commitment to exploring new treatment options for rare diseases, as well as meeting the needs of all patients with skin diseases over the course of their lives.

2 Jul 2014

Forest Laboratories completes acquisition of Furiex Pharmaceuticals

Actavis plc today announced that its subsidiary Forest Laboratories, LLC has successfully completed its acquisition of Furiex Pharmaceuticals, Inc. in an all-cash transaction valued at approximately $1.1 billion, and up to approximately $360 million in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval.

2 Jul 2014

Actavis seeks FDA ANDA approval for generic Zubsolv, confirms patent challenge

Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, Eq, 1.4 mg/0.36 mg and 5.7 mg/1.4 mg Base. Actavis' ANDA product is a generic version of Orexo's Zubsolv, which is a partial opioid agonist indicated for the maintenance treatment of opioid dependence.

30 Jun 2014

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Helsinn Group, the company focused on building quality cancer care, today announces that rights to anamorelin, its innovative ghrelin receptor agonist, have been granted in Turkey to GEN Ilaç.

30 Jun 2014

PD MED trial: Levodopa drug better for long-term treatment of newly diagnosed PD

For long-term treatment of newly diagnosed Parkinson’s disease (PD), the old drug levodopa provides better mobility and a higher quality of life than the two main alternatives, dopamine agonists (DA) and monoamine oxidase type B inhibitors (MAOBI), according to the largest-ever trial of PD treatment (PD MED), published in The Lancet.

13 Jun 2014

P2Y12 and blood clotting: an interview with Dr. Jacobson, NIH

We already understand the many steps involved in blood clotting in great mechanistic detail. The process of blood vessels closing off in response to injury is necessary for preserving life, but blood platelets that are over-active, or activated inappropriately because of unstable plaque, can lead to heart attacks and strokes.

3 Jun 2014

Agonist News and Research

Altering the circadian rhythm: an interview with Dr. Doug Kojetin, The Scripps Research Institute

New approach for understanding auditory localization in patients with hearing aids under background noise

Naltrexone may be effective in diminishing ICD symptoms in PD patients, study finds

GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

Combination superior to monotherapy for COPD

Long-acting inhaled combination therapy best for COPD

New guidelines integrate biomedical advances and behavioral interventions for HIV people

Study demonstrates that Parkinson's patients are more creative than their healthy peers

Sleep problems in PD patients can worsen in later stages of disease

New class of anti-arthritic drugs reduce arthritic joint inflammation and periodontitis

Scientists discover new role for pair of compounds which alter circadian rhythm

Scientists discover new compounds that could alter circadian rhythm

New technology in field of optogenetics can remotely control specific receptors by light

Grunenthal Group submits Marketing Authorization Application to EMA for ZALVISO

Galderma's trifarotene molecule gets FDA Orphan Drug Designation for treatment of congenital ichthyosis

Forest Laboratories completes acquisition of Furiex Pharmaceuticals

Actavis seeks FDA ANDA approval for generic Zubsolv, confirms patent challenge

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

PD MED trial: Levodopa drug better for long-term treatment of newly diagnosed PD

P2Y12 and blood clotting: an interview with Dr. Jacobson, NIH

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News